Compare Nomura Holdings Inc (NMR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Novartis AG — how do they compare? Nomura Holdings Inc trades at $10.84 (market cap $31.31B), while Novartis AG trades at $138.17 (market cap $262.64B). The key difference: Novartis AG is far larger — about 8.4× Nomura Holdings Inc's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NMR | NVS | |
|---|---|---|
Market Cap | $31.31B | $262.64B |
Sector | Financials | Health |
52-Week High | $10.65 | $168.62 |
52-Week Low | $6.73 | $121.80 |
Dividend Yield | 3.05% | 3.44% |
Enterprise Value | — | $303.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $10.63, down 0.19% on the day, with a bullish technical signal driven by moving averages. Recent earnings show mixed quarterly performance but strong annual growth, with revenue reaching $1.66 trillion in 2025 and net income margin at 20.4%. The stock is supported by positive momentum coverage and a solid ROE of 11.03%.
Outlook remains favorable due to valuation metrics like a P/E of 12.46 and bullish analyst sentiment, though risks include volatile cash flows and rising debt-to-asset ratios. Investment opportunity lies in continued wholesale segment growth and ROE expansion, balanced by execution risks in a competitive financial sector.
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
